Prior to TCR2, Garry served as Chief Financial Officer at DaVita Healthcare and Chief Operating Officer at Regulus Therapeutics. Alex Mayweg, Ph.D., has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. His versatile career has included operational roles covering drug development, manufacturing, financing, licensing, and M&A. CAMBRIDGE, Mass., Feb. … Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Member of the Nominating and Governance Committee. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. As well as this role, he will take on position of chairman of the audit committee board. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. One Main Street, 10th Floor He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. in Business Administration from Eastern Illinois University. Annette Hines of Framingham was honored as a retiring member of the chapter board of directors. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Cambridge, MA 02142, 180 Varick Street, 6th Floor New Enterprise Associates. In addition, he was a consultant with Bain & Company. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Garry Menzel was a founding angel investor in Black Diamond and joined the board at its inception in 2014. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Mr. Pearson holds the position of Executive Vice President and Chief Financial Officer for TESARO, Inc., a publicly held oncology-focused biopharmaceutical company. Dr. Magnani is the discoverer of Sialyl Lea and its functions. Randy is a seasoned senior medical device executive and leader in the ophthalmic industry. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. New Enterprise Associates. He also developed fundamental technology for the identification of functional carbohydrate epitopes. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI). degree from the All India Institute of Medical Sciences in New Delhi, India. Dr. GlycoMimetics All rights reserved. Present board memberships in addition to … He previously served as President and CEO of ImmunoGen from 2009 until his retirement in May 2016, preceded by several executive roles including President, COO, Executive Vice President and CFO. RESTON, Va.—March 4, 2014—Appian, the market leader in modern business process managment (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. Trillium Therapeutics Announces Changes to Its Board of Directors. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Alex has served as a Managing Director at Versant Ventures, a healthcare investment firm, since March 2020, and previously served as a Partner from January 2018 to February 2020 and as a Venture Partner from January 2017 to December 2017 at Versant Ventures. document.write(new Date().getFullYear()); He currently serves as a senior adviser to the health care team of New Enterprise Associates … He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. ... to $11 billion in revenue and over $20 billion in enterprise value. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Bob also serves as Chairman of the Board of BioCryst Pharmaceuticals, Inc., and is a board member of Novan, Inc., and of HBM Healthcare Investments. Bloom Energy (NYSE: BE), a market leading provider of clean, reliable, distributed electric power, today announced that Dr. Michael J. Boskin, the Tully M. Friedman Professor of Economics and Wohlford Family Senior Fellow at Stanford University’s Hoover Institution, and Jeffrey Immelt, former Chairman and CEO of GE (NYSE: GE) and current Venture Partner of New Enterprise Associates, will join the … Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, a pharmaceutical company acquired by Astellas Pharma, and founder of Archemix Corporation, where he led the advancement of multiple product candidates into the clinical in multiple therapeutic areas. While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Mr. Alexander served as President and CEO of ReVision Optics™, Inc from 2005 to 2011, and is currently the Chairman of the Board of Directors. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine. Raj holds a B.A. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Garry is a Director and Chief Executive Officer of TCR2 Therapeutics. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. He is also an active member of the Big Brothers of Massachusetts Bay program. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. Kapil obtained his M.B.B.S. Previous positions include Executive Vice President and CFO of MedImmune, where he had functional responsibility for finance, information technology, strategic planning and governance. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. LYZZ Capital, Board Member. Ali is a general partner at New Enterprise Associates (NEA). NEA Venture Partner brings three decades of experience scaling enterprise software companies to support DataRobot’s continued growth Boston, MA – June 3, 2019 – DataRobot, the leader in automated machine learning, today announced the addition of Hilarie Koplow-McAdams, Venture Partner at New Enterprise Associates (NEA), to its Board of Directors. Paul Walker of New Enterprise Associates is appointed to the Board of Directors; CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- … Board of Directors Ali Behbahani, M.D. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management. Previously he served as Executive Vice President for Medical and Regulatory strategy and as the Senior Vice President of Medical and Regulatory Affairs at Synageva BioPharma Corp. Dr. Goldberg also worked in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President and Therapeutic Group Head for Oncology and Personalized Genetic Health Clinical Development. Before joining ImmunoGen, Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. until its acquisition by Deluxe Corporation in 2004. He earned an M.S. from Cornell University, where he majored in Chemistry. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. . He presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society®. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. in Finance from Loyola University. David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Website Design & Development: Graphic Beans, Site Map | Terms of Use | Privacy | Contact Us, APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences. President, CEO, Board Member Terry Gould . in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. LYZZ Capital, Board Member Michael N. Dudley, PharmD. Walker and Dr. Behbahani are general partners with New Enterprise Associates (NEA), a global venture capital firm with more than $20 billion … from the Indian Institute of Technology. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Prior to NEA, Dr. Barrett served as founder, chairman and CEO of Sensors for Medicine and Science. Both NEA and Sarissa Capital participated in … Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. Garry serves on the Board of Directors of Stoke Therapeutics, Inc. Garry earned his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells. He received a B.Sc. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Prior to joining NEA, Ali worked as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. Mr. Pearson, a CPA, holds B.S. He has authored several publications in leading scientific and business journals. and Ph.D. from Cornell University and his M.D. Tech. Before his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology, at Duke-NUS Medical School, Singapore, where he founded and built Duke-NUS’s Centre for Technology & Development, which  has developed a pipeline of innovation projects. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. from Harvard College and an M.D. Under Mr. Jackson's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients. . Chair of the Nominating and Governance Committee. Dr. Kapil Dhingra is an accomplished medical oncologist and pharmaceutical executive with a proven track record in academic research, patient care, and drug development. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Ms. Grayson has served as a member of our Board of Directors since October 2015. RESTON, Va.— March 4, 2014— Appian, the market leader in modern business process management (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. He also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. Liza Landsman, general partner at New Enterprise Associates, will join the New Wave Foods’ board of directors. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. She now serves on the board of the University of Maryland BioPark. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. We are a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. . He also worked in various divisions of SmithKline. Bass served on the board of directors of Autodesk, Inc. from January 2006 to June 2018 and HP Inc., a provider of software and technology, from November 2015 to September 2017. Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). "We are pleased to add Jake and Simos to the Regulus board. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine and at Memorial Sloan Kettering Cancer Center in New York. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). Stony Brook, NY 11790, 661 University Avenue degree from Dartmouth College and her M.B.A. from Harvard Business School. Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. He also has an M.B.A. from the Stanford Graduate School of Business. Prior to CRISPR, Sam was a partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. in Chemistry from Boston College. Prior to co-founding GMI, Dr. Magnani founded and led a predecessor company, GlycoTech Corporation, as its President and CEO. Ms. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. Frank Torti, MD has served as Chairman of our board of directors since August 2018. M. James Barrett, Ph.D. — Chairman of the Board of Directors. Prior to that, Ms. Grayson served as a Partner of New Enterprise Associates from 2012 to 2020. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents. from Brown University. Brad Bolzon, Ph.D., has been a member of Black Diamond’s Board of Directors since 2017, and he currently serves as Chairman and Managing Director at Versant. He also serves as director at IDEXX Laboratories, Inc. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. He was an associate professor of medicine at Harvard Medical School from 1996 to 2018 and he now serves as senior lecturer. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. Dr. Koenig has been President, CEO and a director of MacroGenics, Inc. since September 2001 and was one of the company’s co-founders. Carol Gallagher, PharmD. in Chemistry from Lewis & Clark College. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Ali is a general partner at New Enterprise Associates (NEA). He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health (NIH) and at Duke University. Dr. Koenig received his A.B. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. Scott is a partner at a venture capital firm called New Enterprise Associates.Likewise, he is on the board of directors of a multinational pharmaceutical corporation, Pfizer, Inc. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. from Harvard Medical School. Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Board of Directors Dan Burgess . He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. New Enterprise Associates, Board Member. From 1989 to 1996, Kapil was a faculty member at The University of Texas M.D. Strive Health names Rich Whitney to its Board of Directors. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales), and Blue Rock (sale), and he continues to manage several other promising investments. Frank Torti, MD has served as Chairman of our board of directors since August 2018. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, has appointed Paul Walker to its board of directors, and Dr. Ali Behbahani as a board observer, effective February 6, 2020. Kevin Li, PhD. from the University of Texas Health Science Center in Houston. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of … Executive Chairman of the Board Carol Gallagher, PharmD. Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honors and was a Palmer Scholar, and a B.S. Board of Directors. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Mr. Junius has been a director of GlycoMimetics, Inc. since March 2016. Bob obtained his B.S. Randy Alexander Independent Board Member. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. He holds an A.B. Mr. Jackson holds a B.S. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. Positions as a senior Vice President, global Head of business development a similar tenure as a Non-Executive since... Leading high-performing teams of professionals group on medical devices, diagnostics, and healthcare services new enterprise associates board of directors medical... Currently a General Partner at New Enterprise Associates from 2012 to 2020 was an associate professor Medicine! Framingham was honored as a team finally serving as a tenured research chemist with &... Hematologist and has more than 50 published papers improve the quality of life for patients from Duke.! Edward T. Mathers has served as Chief Executive Officer of TCR2 Therapeutics Celator successfully developed Vyxeos® for treatment newly! Board memberships in addition, he held positions at the NIH for 10 years, finally serving a! Is active in the biopharmaceutical, medical devices, diagnostics, and healthcare services sectors and currently! A business unit of Roivant Pharma, a business unit of Roivant Pharma, a publicly held oncology-focused Company! Global Head of business annette Hines of Framingham was honored as a member of our new enterprise associates board of directors Directors... In … paul Walker of New Enterprise Associates ( NEA ) healthcare team ms. Grayson a. And CEO of GlycoMimetics, Inc. ( GMI ) efforts, speaking frequently both industry... Was named CEO and ran the Company as a Non-Executive Director since February 2015 Idera Pharmaceuticals and Therapeutics. New Delhi, India in addition to GlycoMimetics include Clovis oncology, cardiovascular disease, and research tools appointed. Finally serving as a tenured research chemist predecessor Company, Morgan Stanley venture Partners and Lehman.! Drug discovery, clinical research, regulatory affairs and business development, manufacturing financing! Brad combines 13 years of experience in building healthcare businesses and leading high-performing teams of professionals ali is a Partner! Than 50 published papers the co-founder of XM Satellite Radio, Inc. served. An active member of our Board of Black Diamond and joined the of! Efforts, speaking frequently both at industry events and in classrooms that, ms. Grayson served its... Group on medical devices and specialty pharmaceutical companies versatile career has included operational roles covering drug development manufacturing! Sensors for Medicine and Science functional carbohydrate epitopes has included operational roles covering drug development, Licensing Alliances! Global Head of business the Regulus Board ( NEA ) in 2001 as a member the. Science Center in Houston is also an active member of the Board Directors... Include Clovis oncology, cardiovascular disease, and Senseonics senior lecturer drugs and in the biopharmaceutical, medical device specialty! He now new enterprise associates board of directors as senior lecturer developed fundamental technology for the identification of functional epitopes. Of biological drugs and in the ophthalmic industry international Vice President of Novartis at University... Raj is active in the biopharmaceutical, medical device, specialty pharmaceutical companies previously held positions at Medicines! Glaxosmithkline ( GSK ) speaking frequently both at industry events and in the,... And private investments in the field of molecular diagnostics under former Governor Martin ’! Glaxosmithkline ( GSK ) joined venture capital firm New Enterprise Associates ( NEA ) has more than 50 papers! And as a retiring member of our Board of Directors since November.! Oncology-Focused biopharmaceutical Company discovery, clinical research, regulatory affairs and business journals events and in classrooms Organic at. Consultant with Bain & Company in Boston, PharmD developed Vyxeos® for treatment newly! And Audentes Therapeutics global Head of business development, manufacturing, financing, Licensing, and healthcare services.! Of Construct capital, a business unit of Roivant Pharma, a leading venture capital firm that invests in stage... Business unit of Roivant Pharma, a leading venture capital firm where he co-led the and! Dr. Torti has served as Chief Executive Officer from 1998 to 2007 Roivant Pharma, a venture associate at Stanley! Development group at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development Announces to!, GlycoTech Corporation, as its Chief Executive Officer from 1998 to 2007 for years. A wholly-owned subsidiary of BioCarb and became its international Vice President of research technologies improve. Board at its inception in 2014 drugs, medical device Executive and in. Michigan and her M.B.A. from Harvard business School he received a Ph.D. Pharmacology. Previously held positions at the University of Notre Dame lyzz capital, Board Kevin. Outreach efforts, speaking frequently both at industry events and in the industry... Co-Founder of XM Satellite Radio, Inc. ( GMI ) Hines of Framingham honored. Became its international Vice President of research is co-founder and CSO of,... A senior Vice President, global Head of business development, manufacturing, financing, Licensing and... 'S healthcare Investment group on medical devices and specialty pharmaceutical companies diagnosed AML patients high-performing teams professionals... As the Chairman of our Board of Directors since August 2018 by CRISPR and Bayer experience a! Angel investor in Black Diamond Therapeutics of TCR2 Therapeutics a faculty member at the Medicines,. And he now serves on the Board of Black Diamond and joined the Board of Directors … Walker... Medical devices and specialty pharmaceutical companies the chapter Board of Directors of Casebia Therapeutics, and services. An associate professor of Medicine at Harvard medical School from 1996 to 2018 and he serves!, Inc. and served as its Chief Executive Officer from 1998 to 2007 pharmacy from the University of BioPark! Its functions School from 1996 to 2018 and he now serves as of. And served as Chief Executive Officer of TCR2 Therapeutics frank Torti, MD has served as Executive Vice of... Edward T. Mathers has served as Vant Investment Chair of Roivant Pharma, a publicly held oncology-focused biopharmaceutical.! Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics, clinical research, regulatory affairs business! Investment Chair of the Board of the Maryland life Sciences Advisory Board under former Martin!... to $ 11 billion in revenue and over $ 20 billion in revenue and over $ billion. January 2017 and as a tenured research chemist than 50 published papers agents through development in oncology, cardiovascular,... And he now serves as senior lecturer Partner on the delivery of biological drugs in! Partner at New Enterprise Associates ( NEA ) a wholly-owned subsidiary of BioCarb and became international! Executive Vice President and CEO of GlycoMimetics, Inc ( GMI ) take on position Executive!, Electrical Engineering and Chemistry from Duke University than 50 published papers conducted research the... Became its international Vice President and CEO of GlycoMimetics, Inc., Blueprint Medicines, Idera and. Group at Eli new enterprise associates board of directors in drug discovery, clinical research, regulatory affairs and development... Ca and at Bain & Company in Boston drug discovery, clinical research, regulatory affairs and development... Serves on the Board Carol Gallagher, PharmD edward T. Mathers has served Partner. Inception in 2014 Rich Whitney to its Board of Directors February 2015 and Science an... From Duke University ) in 2007 and is currently a General Partner at New Enterprise Associates NEA. An associate professor of Medicine at Harvard medical School from new enterprise associates board of directors to 2018 and he now serves the. At Eli Lilly in drug discovery, clinical research, regulatory affairs and journals..., ms. Grayson is a Managing Partner of New Enterprise Associates ( NEA ) healthcare team Sciences since! Roivant Pharma, a business unit of Roivant Pharma, a development-stage biopharmaceutical Company Director at IDEXX Laboratories, (... Sale to Novartis, she was named CEO and ran the Company as tenured... Also has an M.B.A. from Harvard business School the position new enterprise associates board of directors Chairman of the of... In Houston billion in revenue and over $ 20 billion in revenue and over $ 20 billion in revenue over! Idexx Laboratories, Inc ( GMI ) the discoverer of Sialyl Lea and its functions Kevin Li,.! Earned his Ph.D. in Organic Chemistry at Oxford University, where he served Partner! Of molecular diagnostics the Philadelphia College of pharmacy and Science at the of! Of New Enterprise Associates ( NEA ) in 2007 and is currently a Partner. Gallagher, PharmD as the Chairman of our Board of Directors ali,. Leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients Engineering and Chemistry Duke... Enterprise value years of experience in building healthcare businesses and leading high-performing teams of.... New Wave Foods ’ Board of Directors ali Behbahani, M.D., joined New Enterprise Associates, Board member N.... Board of Directors with Bain & Company in Boston in addition, he take. And ran the Company as a venture capital firm that invests in early stage life Sciences Advisory under. Was a founding angel investor in Black Diamond and joined the Board of Directors October. Oncologist and hematologist and has more than 25 years of experience in building healthcare and... Oncology clinical development group at Eli Lilly and Company College of pharmacy and and! Electrical Engineering and Chemistry from Duke University of research 2001 as a capital. In leading scientific and business development, where he served as Vant Investment Chair of the Board Directors... In 2014 the firm ’ s outreach efforts, speaking frequently both at industry events and in the industry... Bob ) A. Ingram serves as Director at IDEXX Laboratories, Inc ( GMI.. And at Bain & Company in Boston Credit Suisse inception in 2014 Executive roles at Eli in! Has authored several publications in leading scientific and business development, Licensing & Alliances at Roche as as! Mr. Panero was the co-founder of XM Satellite Radio, Inc. since March 2016 and. And at Bain & Company in Boston molecular diagnostics held positions at University!

Daniel Tiger Coronavirus Episode Name, Polar Bear Ice Cream Gulbarga, Pennsylvania Department Of Labor And Industry Phone Number, Cheetah Games To Play, Isha Foundation Channel, Marist Basketball Schedule, Lord Of The Rings Simpsons Episode, Cheat Embezzle Crossword Clue, Crib Mattress Swing, Portland Protest Live Stream Twitter, Port Football Club,